
Vertex Pharmaceuticals Incorporated VRTX
$ 476.44
-1.97%
Annual report 2025
added 02-13-2026
Vertex Pharmaceuticals Incorporated Total Non Current Liabilities 2011-2026 | VRTX
Annual Total Non Current Liabilities Vertex Pharmaceuticals Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 898 M | 690 M | 696 M | 766 M | 899 M | 870 M | 565 M | 1.13 B | 846 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 B | 565 M | 818 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Apellis Pharmaceuticals
APLS
|
289 M | $ 20.13 | -2.75 % | $ 2.54 B | ||
|
Aptorum Group Limited
APM
|
2.21 M | $ 0.8 | -4.99 % | $ 4.36 M | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Axsome Therapeutics
AXSM
|
48.9 M | $ 163.18 | -1.92 % | $ 8.12 B | ||
|
AbCellera Biologics
ABCL
|
326 M | $ 3.64 | -4.84 % | $ 1.09 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
648 K | $ 23.82 | -0.25 % | $ 2.91 B | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Corvus Pharmaceuticals
CRVS
|
2.31 M | $ 17.04 | -4.75 % | $ 818 M | ||
|
Champions Oncology
CSBR
|
1 M | $ 5.98 | -1.48 % | $ 81.7 M | ||
|
Daré Bioscience
DARE
|
1.39 M | $ 1.59 | -1.27 % | $ 13.5 M | ||
|
DBV Technologies S.A.
DBVT
|
7.14 M | $ 21.94 | -5.66 % | $ 2.13 B | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Capricor Therapeutics
CAPR
|
4.86 M | $ 25.4 | -5.44 % | $ 680 M | ||
|
Eton Pharmaceuticals
ETON
|
4.56 M | $ 17.58 | -3.14 % | $ 451 M | ||
|
Exelixis
EXEL
|
63.6 M | $ 40.7 | -0.8 % | $ 11.1 B | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Fennec Pharmaceuticals
FENC
|
30.9 M | $ 7.91 | -3.77 % | $ 210 M | ||
|
Amicus Therapeutics
FOLD
|
245 M | $ 14.35 | -0.1 % | $ 4.43 B | ||
|
Galectin Therapeutics
GALT
|
52 K | $ 2.95 | -3.59 % | $ 184 M | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Galapagos NV
GLPG
|
2.41 B | $ 32.63 | -4.28 % | $ 2.69 B | ||
|
Codexis
CDXS
|
28.2 M | $ 0.98 | -3.85 % | $ 71.9 M | ||
|
Greenwich LifeSciences
GLSI
|
9.5 M | $ 26.25 | -4.16 % | $ 342 M | ||
|
Galecto
GLTO
|
541 K | $ 28.88 | -3.91 % | $ 767 M | ||
|
Genmab A/S
GMAB
|
769 M | $ 27.42 | -7.52 % | $ 17.6 B | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Gossamer Bio
GOSS
|
37.2 M | $ 0.44 | 3.03 % | $ 67.2 M | ||
|
GeoVax Labs
GOVX
|
14.7 K | $ 1.52 | -2.88 % | $ 2.76 M | ||
|
Grifols, S.A.
GRFS
|
7.22 B | $ 8.51 | -6.38 % | $ 6.83 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
264 M | $ 3.19 | -4.49 % | $ 1.14 M | ||
|
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | ||
|
Halozyme Therapeutics
HALO
|
388 M | $ 68.8 | -1.5 % | $ 8.24 B | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
157 M | $ 28.35 | -2.91 % | $ 1.64 B | ||
|
Hoth Therapeutics
HOTH
|
2.71 K | $ 0.98 | -3.92 % | $ 6.25 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M |